文献速递妇科

使用BRCAPRO和Myriad模型预测韩国卵巢癌患者的BRCA1和BRCA2突变

BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
PubMed 文献 · Gynecol Oncol · 2017-02-01

该研究在韩国单中心招募2010年11月至2016年8月接受BRCA基因检测的232例卵巢癌患者,比较BRCAPRO与Myriad模型预测的BRCA突变携带概率与实际突变状态。BRCAPRO和Myriad的受试者工作特征曲线下面积分别为0.720和0.747,两模型在有家族史患者中均高估突变概率,在无家族史患者中均低估。作者认为两模型似乎可作为韩国卵巢癌患者BRCA突变风险评估的可接受工具。

要点

  • 232例患者中57例(24.6%)BRCA突变阳性,其中BRCA1突变41例、BRCA2突变16例。
  • BRCAPRO和Myriad预测BRCA突变的AUC分别为0.720和0.747。
  • 两模型在有家族史者中高估突变概率,在无家族史者中低估。

核心结论

  • BRCAPRO和Myriad似乎可作为韩国卵巢癌患者BRCA突变风险评估的可接受工具。

研究设计与样本

  • 研究为在韩国单中心妇产科招募2010年11月至2016年8月接受BRCA基因检测的个体,共232例,其中99.1%(230/232)为韩国族裔。
  • 232例中206例为卵巢癌、26例为乳腺/卵巢双原发癌,36例有一级亲属乳腺癌/卵巢癌家族史。

主要发现

  • 57例(24.6%)BRCA突变阳性,其中BRCA1突变41例、BRCA2突变16例。
  • 全部患者BRCAPRO和Myriad平均评分分别为6.4%和7.7%。
  • BRCA突变阳性患者评分显著高于阴性患者:BRCAPRO 29.0% vs 6.1%(P<0.001),Myriad 12.1% vs 7.7%(P<0.001)。
  • BRCAPRO和Myriad预测BRCA突变风险的受试者工作特征曲线下面积分别为0.720和0.747。
  • 两模型在有乳腺癌/卵巢癌家族史患者中分别高估突变概率1.55倍和1.50倍,在无家族史患者中均低估为0.54倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the predictive efficacies including sensitivity and positive predictive value of the genetic risk prediction model BRCAPRO and the Myriad BRCA risk calculator in Korean ovarian cancer patients. METHODS: Individuals undergoing genetic testing for BRCA mutations from November 2010-August 2016 were recruited from the Department of Obstetrics and Gynecology at a single institute in Korea. The observed BRCA1 and BRCA2 mutation statuses were compared with the predicted carrier probabilities using BRCAPRO and the Myriad BRCA risk calculator. RESULTS: Two hundred thirty-two patients were recruited, of whom 99.1% (230/232) were of Korean ethnicity. Of the 232 individuals, 206 and 26 had ovarian and double primary breast/ovarian cancer, respectively. Thirty-six individuals had a family history of breast/ovarian cancer in first-degree relatives. Fifty-seven patients (24.6%) tested positive for BRCA mutation (41 BRCA1, 16 BRCA2). The mean BRCAPRO and Myriad scores for all patients were 6.4% and 7.7%, respectively. The scores were significantly higher for patients with positive BRCA mutation status (29.0% vs. 6.1%, P<0.001, 12.1% vs. 7.7%, P<0.001, respectively). For all patients, the respective areas under the receiver operating characteristics curves were 0.720 and 0.747 for the BRCAPRO and Myriad models to predict the risk of carrying a BRCA mutation. Both models overestimated the mutation probability in patients with a family history of breast/ovarian cancer (1.55-fold and 1.50-fold, respectively) and underestimated the probability in patients without a family history (both, 0.54-fold). CONCLUSION: BRCAPRO and Myriad seem to be acceptable risk assessment tools for determining the risk of carrying BRCA mutations in Korean ovarian cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Eoh KJ, Park JS, Park HS, et al. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. Gynecol Oncol. 2017. PMID: 28159408. doi:10.1016/j.ygyno.2017.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。